SCHEMBL4838892

SCHEMBL4838892

CC(Nc1nccc(N(C(=O)Nc2cccc(F)c2)c2ccccc2)n1)C(C)(C)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.67
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
MTOR P42345 1/20 0.39
MEN1 O00255 1/20 0.38
ATM Q13315 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38
PIM1 P11309 1/20 0.38
PRKACA P17612 1/20 0.38
CDK2 P24941 1/20 0.38
FLT3 P36888 1/20 0.38
MAPK8 P45983 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CDK8 P49336 1/20 0.38
CLK2 P49760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838900 1.00 MAPK14 (0.67) MAPK14NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4840721 0.94 MAPK14 (0.72) MAPK14NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4840708 0.94 MAPK14 (0.72) MAPK14NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4840138 0.91 MAPK14 (0.70) MAPK14NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4840147 0.91 MAPK14 (0.70) MAPK14NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4828937 0.91 MAPK14 (0.77) MAPK14KMT2AMTORMEN1
SCHEMBL4828889 0.90 MAPK14 (0.68) MAPK14NPC1RAB9ADAPK3PRKD3
SCHEMBL4828877 0.90 MAPK14 (0.68) MAPK14NPC1RAB9ADAPK3PRKD3
SCHEMBL4836051 0.89 MAPK14 (0.73) MAPK14KMT2ASMN1; SMN2MEN1
SCHEMBL4836044 0.89 MAPK14 (0.73) MAPK14KMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US claimed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US claimed
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US disclosed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors IL1B, IL1A, IL6 MAPK14 2674/4885NPC1 3402/4885RAB9A 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.